Exicure to Present at Spring Investor Summit 2019
SKOKIE, Ill.--(BUSINESS WIRE)--Mar 26, 2019--Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CFO, David Snyder, will give a company presentation on Tuesday, April 2, 2019 at 9:30 am ET at the Spring Investor Summit. The presentation will be made at the Essex House in New York City.
A live audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure’s proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005224/en/
CONTACT: Karen Sharma
KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Exicure, Inc.
Copyright Business Wire 2019.
PUB: 03/26/2019 07:00 AM/DISC: 03/26/2019 07:00 AM